Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30882179 | 1.00 | ALDH1A1 (0.50) | ALDH1A1RAB9AHTTNPC1CYP2C19 | |
| SCHEMBL188322 | 0.85 | MAPT (0.46) | ALDH1A1HTTSMN1; SMN2POLBPKM | |
| SCHEMBL16887793 | 0.82 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2POLBMAPTTDP1 | |
| SCHEMBL16168119 | 0.82 | KEAP1 (0.49) | ALDH1A1RAB9AGAAMAPT | |
| SCHEMBL9779937 | 0.82 | NPC1 (0.50) | ALDH1A1RAB9AHTTNPC1CYP2C19 | |
| SCHEMBL2321145 | 0.81 | MAPT (0.52) | ALDH1A1RAB9AHTTNPC1CYP2C19 | |
| SCHEMBL22023198 | 0.80 | CA1 (0.38) | ALDH1A1MAPTTDP1 | |
| SCHEMBL4015400 | 0.80 | LIPC (0.46) | ALDH1A1PKM | |
| Hydrochloric Acid SCHEMBL5191651 | 0.80 | ALDH1A1 (0.39) | ALDH1A1RAB9AHTTNPC1CYP2C19 | |
| SCHEMBL9744548 | 0.79 | CLCN2 (0.46) | ALDH1A1RAB9AGAAPKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117902992-A | Preparation method of 2, 4-difluorophenyl glycine | 浙江永太科技股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4687443-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | Genepep (FR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024208878-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | GENEPEP (FR) | 2024-10-10 | — | — | WO | disclosed |
| CN-117902992-A | Preparation method of 2, 4-difluorophenyl glycine | 浙江永太科技股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117902992-A | Preparation method of 2, 4-difluorophenyl glycine | 浙江永太科技股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117902992-A | Preparation method of 2, 4-difluorophenyl glycine | 浙江永太科技股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11858894-B2 | Crystalline form of 1-(5-(2,4-Difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-n-methylmethanamine salt | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | disclosed |
| CN-110637009-B | Process for preparing intermediates for 4-methoxypyrrole derivatives | 株式会社大熊制药 | 2023-11-10 | — | — | CN | disclosed |
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | Karoyan, Philippe (FR) | 2023-09-19 | — | — | US | disclosed |
| US-6566338-B1 | Administering caspase inhibitor for therapy of oral mucositis, gastrointestinal mucositis, bladder mucositis or proctitis resulting from chemotherapy or radiation therapy of cancer in an animal | CYTOVIA, INC. | 2003-05-20 | — | — | US | disclosed |
| EP-1307214-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1076563-A4 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | INVITROGEN CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-1220869-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | Cytovia, Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2002013848-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001027140-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | CYTOVIA, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1076563-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6153591-A | PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS | CYTOVIA, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999047154-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | VIP, RNASE1, ABCB11 | ALDH1A1 1766/4885RAB9A 2903/4885HTT 1669/4885 |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | VIP, RNASE1, ABCB11 | ALDH1A1 1766/4885RAB9A 2903/4885HTT 1669/4885 |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | CD44, HLA-C, HLA-A | ALDH1A1 621/4885RAB9A 3935/4885HTT 2940/4885 |
| US-11858894-B2 | Crystalline form of 1-(5-(2,4-Difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-n-methylmethanamine salt | FIS1, FH, SUCNR1 | ALDH1A1 697/4885RAB9A 2784/4885HTT 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.